COSMOS Pharmaceutical Full Year 2025 Earnings: In Line With Expectations

Simply Wall St · 09/02/2025 22:37

COSMOS Pharmaceutical (TSE:3349) Full Year 2025 Results

Key Financial Results

  • Revenue: JP¥1.01t (up 4.8% from FY 2024).
  • Net income: JP¥31.0b (up 27% from FY 2024).
  • Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue.
  • EPS: JP¥391 (up from JP¥309 in FY 2024).
earnings-and-revenue-growth
TSE:3349 Earnings and Revenue Growth September 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

COSMOS Pharmaceutical Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in Japan.

Performance of the Japanese Consumer Retailing industry.

The company's shares are down 5.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of COSMOS Pharmaceutical's balance sheet and an in-depth analysis of the company's financial position.